# Junta clínica — PT-pseudo_d3e975d025e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d3e975d025e6",
  "pid": "PT-pseudo_d3e975d025e6",
  "task": 1,
  "psa": 15.8,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.318,
  "psav": 0.96,
  "psap": 15.4,
  "vol": 49.63,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.84823215,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "69 kg",
    "height": "179 cm",
    "bmi": "21.5",
    "bp": "127/86 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results."
    },
    {
      "s": "History",
      "t": "First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly."
    }
  ],
  "occupation": "tram driver",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "6 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3e975d025e6
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 15.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.318 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 15.4 ng/mL
  - Prostate volume: 49.63 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84823215 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.

Vitals: weight 69 kg, height 179 cm, BMI 21.5, BP 127/86 mmHg, HR 72 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results.

History: First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly.

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.86
  uncertainty  +/- 0.05 epistemic (95% band 0.75-0.96); among patients I cannot tell apart the outcome was 0.60 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 23 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.80: PI-RADS 5, PSA 12.0, PSAD 0.411, age 71, DRE Normal -> BIOPSY (borderline). He wrote: "P5 in 71 years old patient with no major comorbidities"
  2. distance 1.85: PI-RADS 5, PSA 17.0, PSAD 0.462, age 61, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 61 year patient"
  3. distance 1.87: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that MRI-directed prostate biopsy is the standard of care, although MRI in-bore biopsy is offered in a few centres. "MRI-directed US-guided prostate biopsy is now the standard of care, although MRI in-bore biopsy is offered in a few centres." This requires consideration of the PI-RADS score in determining the biopsy strategy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of biopsy is not settled because the guideline requires a specific risk-adapted approach based on the PI-RADS score and PSA density. Expert-Cohort's criterion, which mandates biopsy for PI-RADS 3 or higher, is a specific threshold that the guideline uses to guide the decision, which is not superseded by the general suggestion.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None means the indication stands, as the guideline requires consideration of prior biopsy status in the overall strategy.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: 0.96 ng/mL/yr is a factor that must be considered in the overall risk assessment.
laboratory_results - the PSA density: 0.318 ng/mL/cc is a factor that must be considered in the overall risk assessment.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the details from the MRI report, PSA trend, and previous notes to determine the appropriate risk-adapted biopsy strategy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the significance of the PSA velocity (0.96 ng/mL/yr) in the overall risk assessment.
  previous_notes (get_previous_notes) -> Determine the prior biopsy status and any existing surveillance protocol.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend reveal about the PSA velocity in the context of the PI-RADS 5 score?
  Q3. What does the previous_notes state regarding the prior biopsy status and surveillance protocol?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "discrete, low-signal area within the left peripheral zone, spanning the base through the mid-gland, spanning roughly 18 mm at its widest."

psa_trend
the significance of the PSA velocity (0.96 ng/mL/yr) in the overall risk assessment: The PSA trend shows a rise from 3.9 (Jan 2023) to 15.8 (Jan 2025), with a velocity of 0.96 ng/mL/yr calculated over the period.

previous_notes
the prior biopsy status and any existing surveillance protocol: Prior biopsy status is "None". There is no explicit surveillance protocol mentioned in the retrieved notes.

WHAT I DID NOT OPEN
laboratory_results, family-history of prostate cancer (anamnesis) because they were not explicitly requested by the Moderator's fixed plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm, as per the radiology_report.
PSA velocity of 0.96 ng/mL/yr in the context of a PI-RADS 5 score, as per the psa_trend.

AGAINST sampling this patient now
Prior biopsy status is "None", which is a factor that might suggest deferral if the guideline emphasized prior biopsy status strongly.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 15.80 ng/mL over 5 points spanning 24 months; velocity +5.88 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 24.1 ng/mL, conformal 95% band 6.9-84.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.78
  uncertainty  +/- 0.07 epistemic (95% band 0.64-0.93), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.86  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.78  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have answered all three moderator questions. The `radiology_report` addressed Q1 by stating "COMPARISON: new". The `psa_trend` addressed Q2 by detailing the PSA velocity of 0.96 ng/mL/yr in the context of the PI-RADS 5 score. The `previous_notes` addressed Q3 by stating the prior biopsy status is "None" and noting no explicit surveillance protocol.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the finding that the prior biopsy status is "None" aligns with the rationale that the indication stands, as noted by the Registrar.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study? Answered by the Registrar: "COMPARISON: new".
Q2. What does the psa_trend reveal about the PSA velocity in the context of the PI-RADS 5 score? Answered by the Registrar: "The PSA trend shows a rise from 3.9 (Jan 2023) to 15.8 (Jan 2025), with a velocity of 0.96 ng/mL/yr calculated over the period."
Q3. What does the previous_notes state regarding the prior biopsy status and surveillance protocol? Answered by the Registrar: "Prior biopsy status is 'None'. There is no explicit surveillance protocol mentioned in the retrieved notes."

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score is the most decisive variable as it directly triggered the EXPERT-COHORT criterion, which is the basis for the PANEL-PROTOCOL's decision. The PSA velocity (0.96 ng/mL/yr) combined with the new, large lesion size (18 mm) in the MRI report further strengthens the indication for intervention according to the EAU guideline's emphasis on risk stratification.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with biopsy, as the retrieved evidence confirms the high-risk features (PI-RADS 5, rising PSA velocity) that align with the panel's conclusion and the EAU guideline's standard of care for such findings.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

67y male, PSA 15.8, PSAD 0.318, biopsy-naive, PI-RADS 5. The PI-RADS 5 finding mandates biopsy, supported by the elevated PSA density. No prior pathology exists to alter this decision.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
